Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.

Journal article

BACKGROUND and AIMS: Budesonide is a corticosteroid with minimal systemic corticosteroid activity due to first-pass hepatic metabolism. Budesonide MMX® is a once-daily oral formulation of budesonide that extends budesonide release throughout the colon using multi-matrix system (MMX) technology. METHODS: We performed a randomized, double-blind, double-dummy, placebo-controlled trial to evaluate the efficacy of budesonide MMX for induction of remission in 509 patients with active, mild to mode...

Expand abstract

Authors: Sandborn, W; Travis, S; Moro, L; Jones, R; Gautille, T

• Publication status: Published
• Journal: Gastroenterology
• Volume: 143
• Issue: 5
• Pages: 1218-26.e1-2
• Publication date: 2012-11-01
• DOI: 10.1053/j.gastro.2012.08.003
• EISSN: 1528-0012
• ISSN: 0016-5085
• Language: English
• Keywords: Middle Aged; Anti-Inflammatory Agents; Adult; Treatment Outcome; Humans; Delayed-Action Preparations; Budesonide; Adolescent; Aged; Colitis, Ulcerative; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Intention to Treat Analysis; Female; Male; Remission Induction; Mesalamine; Young Adult